CRISPR Therapeutics - Strategy, SWOT and Corporate Finance Report
CRISPR Therapeutics - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.
CRISPR Therapeutics AG (CRISPR or the company) is a biopharmaceutical company created to translate CRISPR-Cas9, a breakthrough gene-editing technology, into transformative medicines for serious human diseases. The company classifies its business into single operating segment: the business of discovering, developing and commercializing therapies derived from or incorporating genome-editing technology. Through its CRISPR/Cas9 gene-editing technology, the company allows selective deletion, modification or correction of a disease causing abnormality in a specific DNA segment. It primarily operates in Switzerland, the UK, and the US. The company is headquartered in Basel, Switzerland.
Detailed information on CRISPR Therapeutics required for business and competitor intelligence needs
A study of the major internal and external factors affecting CRISPR Therapeutics in the form of a SWOT analysis
An in-depth view of the business model of CRISPR Therapeutics including a breakdown and examination of key business segments
Intelligence on CRISPR Therapeutics's mergers and acquisitions (MandA), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
News about CRISPR Therapeutics, such as business expansion, restructuring, and contract wins
Large number of easy-to-grasp charts and graphs that present important data and key trends
Reasons to buy
Gain understanding of CRISPR Therapeutics and the factors that influence its strategies.
Track strategic initiatives of the company and latest corporate news and actions.
Assess CRISPR Therapeutics as a prospective partner, vendor or supplier.
Support sales activities by understanding your customers' businesses better.
Stay up to date on CRISPR Therapeutics's business structure, strategy and prospects.